I Peace, Inc., a GMP-compliant CDMO specialising in induced pluripotent stem cells (iPSCs), has entered into a collaboration with US-based Vita Therapeutics to co-develop universal iPS cell lines intended for use in allogeneic cell transplantation therapies. The project will utilise
Flamma, a global contract development and manufacturing organisation (CDMO), has announced the grand opening of a new current Good Manufacturing Practice (cGMP) facility in Dalian, China. The plant will enhance the company’s capacity to produce and commercialise small molecule active
Hongene Biotech Corporation, a contract development and manufacturing organisation (CDMO) focused on nucleic acid therapeutics, has played a central role in progressing DNV001, a novel GalNAc-conjugated siRNA therapy developed by Hangzhou Dingle Xinwei Biotechnology. The investigational new drug (IND) application
Myrtelle Inc. has commenced commercial-stage manufacturing for its investigational gene therapy product, MYR-101, developed for the treatment of Canavan disease. The initiative marks a key milestone in the company’s journey toward market readiness and expanded patient access. The manufacturing programme
GC Cell has announced a CDMO agreement with Dewcell, a Korean biotech firm developing stem cell-derived artificial platelets. The partnership will focus on the production and clinical readiness of Dewcell’s lead candidate, DCB-101 (en-aPLT), aimed at addressing chronic blood supply
Aenova has expanded its advanced technology offering with the introduction of a hot melt extrusion (HME) platform at its Regensburg, Germany site. The platform enables the production of amorphous solid dispersions (ASDs) for active pharmaceutical ingredients (APIs) up to Occupational
Merck, known as MSD outside the United States and Canada, has announced a definitive agreement to acquire Verona Pharma plc for $107 per American Depository Share, representing a total transaction value of approximately $10 billion. The move strengthens Merck’s cardio-pulmonary
Alvotech, a global biotech company focused on biosimilars, has announced the acquisition of Switzerland-based Ivers-Lee Group, a specialist in assembly and packaging for the pharmaceutical industry. While Ivers-Lee will remain a separate legal entity, it will be integrated into Alvotech’s
Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a contract development organisation based in Nijmegen, the Netherlands. Avivia specialises in formulation development, analytical method development, and excipient characterisation. The acquisition supports Ofichem’s strategic aim to become a
Amarna Therapeutics has entered into a formal agreement with NorthX Biologics to support the continued development and manufacturing of Nimvec™ AM510, a gene therapy candidate aimed at treating Type 1 Diabetes (T1D). The agreement follows a previously announced strategic partnership between the two
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
